Evidence map›Paper›PMID 25311932›Full record

ArticleLipids in health and disease2014

Polymorphisms of genes involved in lipid metabolism and risk of chronic kidney disease in Japanese - cross-sectional data from the J-MICC study.

Asahi Hishida, Kenji Wakai, Mariko Naito, Shino Suma, Tae Sasakabe, Nobuyuki Hamajima, Satoyo Hosono, Mikako Horita, Tanvir Chowdhury Turin, Sadao Suzuki and 8 more

Open access · goldAbstract read
In one paragraph

Article in Lipids in health and disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 3 countries.

Asahi HishidaDepartment of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan. a-hishi@med.nagoya-u.ac.jp.
Kenji Wakai
Mariko Naito
Shino Suma
Tae Sasakabe
Nobuyuki Hamajima
Satoyo Hosono
Mikako Horita
Tanvir Chowdhury Turin
Sadao Suzuki
Tara Sefanya Kairupan
Haruo Mikami
Keizo Ohnaka
Isao Watanabe
Hirokazu Uemura
Michiaki Kubo
Hideo Tanaka
J-MICC Study Group
Nagoya University · JPAichi Cancer Center · JPKagoshima University · JPKyushu University · JPShiga University of Medical Science · JPKyoto Prefectural University of Medicine · JPRIKEN Center for Integrative Medical Sciences · JPSaga University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic kidney disease (CKD) is known to be one of the causes of cardiovascular disease and end-stage renal disease. Among the several treatable risk factors of CKD, that of dyslipidemia is relatively controversial. To clarify the association of polymorphisms in genes involved in lipid metabolism with the risk of CKD in the Japanese population, we used cross-sectional data from the Japan Multi-Institutional Collaborative Cohort (J-MICC) Study.

methodsA total of 3,268 men and women, aged 35-69 years, were selected from J-MICC Study participants for inclusion in this study. Twenty-eight candidate single nucleotide polymorphisms (SNPs) were selected in 17 genes associated with the risk of lipid metabolism disorders, and genotyping of the subjects was conducted using the multiplex PCR-based invader assay. The prevalence of CKD was determined for stages 3-5 (defined as estimated glomerular filtration rate <60 ml/min/1.73 m2).

resultsLogistic regression analysis revealed that SNPs APOA5 T - 1131C (rs662799), APOA5 T1259C (rs2266788), TOMM40 A/G (rs157580), and CETP TaqIB (rs708272) were significantly associated with CKD risk in those individuals genotyped, with age- and sex-adjusted odds ratios (ORs) per minor allele (and 95% confidence intervals (CIs)) of OR 1.22 (95% CI: 1.06-1.39), 1.19 (1.03-1.37), 1.27 (1.12-1.45), and 0.81 (0.71-0.92), respectively. Analysis of the gene-environment interaction revealed that body mass index (BMI) was a significant effect modifier for APOA5 T - 1131C (rs662799) and a marginally significant effect modifier for APOA5 T/C (rs2266788), with the interaction between BMI ≥30 and individuals with at least one minor allele of each genotype of OR 10.43 (95% CI: 1.29-84.19) and 3.36 (0.87-13.01), respectively.

conclusionsFour polymorphisms in APOA5, TOMM40, and CETP were shown to be significantly associated with CKD risk, and a significant interaction between the two APOA5 SNPs and BMI on CKD risk was also demonstrated. This suggests the future possibility of personalized risk estimation for this life-limiting disease.

Indexed as

Polymorphism, Single NucleotideAdultAgedApolipoprotein A-VApolipoproteins ABody Mass IndexCross-Sectional StudiesFemaleGene FrequencyGenetic Association StudiesGenetic Predisposition to DiseaseGlomerular Filtration RateHumansJapanLinkage DisequilibriumLipid MetabolismAPOA5 protein, humanApolipoprotein A-VApolipoproteins A

Identifiers

PMID25311932
PMCPMC4210508
OpenAlexW1981987255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.